logo

For the Inventor, By the Inventor

Odense, Denmark

Jens Christian Jensenius

This inventor holds 8 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignees: Novo Industri A/s, Other. Active years: 1990-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jens Christian Jensenius. Retrieved from https://idiyas.com/inventor/jens-christian-jensenius

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8 

% Patents Active = 75.0


Average Co-Inventor Count = 1.7

ph-index = 6

Forward Citations = 141(Granted Patents)


Location History:

  • Odense, DK (1990)
  • 5230 Odense M, DK (1994)
  • Odense M, DK (1992 - 2006)
  • DK-5230 Odense, DK (2003 - 2008)

Company Filing History:

goldMedal2 out of 103 
 
Novo Industri A/s
 patents
silverMedal6 out of 834,659 
Other
 patents

Years Active: 1990-2008

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 7439224 - Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromised individuals (2008-10-21),
2. 7202207 - Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals (2007-04-10),
3. 7112414 - Masp-2, a complement-fixing enzyme, and uses for it (2006-09-26),
4. 6846649 - Recombinant human mannan-binding lectin (2005-01-25),
5. 6562784 - Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals (2003-05-13),
6. 5338661 - Monoclonal antibody specific for a human tumour-associated antigen (1994-08-16),
7. 5132287 - Methods of treating disorders which cause conglutinin deficiency (1992-07-21),
8. 4906734 - Human conglutinin (1990-03-06),

Title: Innovations by Jens Christian Jensenius

Introduction

Jens Christian Jensenius is a notable inventor based in Odense, Denmark. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of eight patents to his name, Jensenius has focused on developing treatments for immunocompromised individuals.

Latest Patents

One of Jensenius's latest patents involves the use of mannan-binding lectin (MBL) in the treatment of infections in immunocompromised individuals. This invention relates to a composition that includes at least one MBL subunit or oligomer, which can be manufactured into a medicament for prophylaxis and treatment of infections. The invention is particularly relevant for individuals suffering from neutropenia, especially those undergoing chemotherapy or similar treatments. It has been shown that individuals with serum MBL levels ranging from 50 ng/ml to 500 ng/ml can benefit from this treatment, regardless of their serum MBL levels.

Career Highlights

Throughout his career, Jensenius has worked with prominent companies, including Novo Nordisk A/S. His work has significantly impacted the development of medical treatments aimed at improving the health of immunocompromised patients.

Collaborations

Jensenius has collaborated with notable colleagues such as Steffen Thiel and Thomas Vorup Jensen. Their combined expertise has contributed to the advancement of research in immunology and treatment methodologies.

Conclusion

Jens Christian Jensenius is a distinguished inventor whose work in immunology has led to innovative treatments for immunocompromised individuals. His contributions continue to influence the medical field and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…